You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股全線暴跌!主要兩個原因
格隆匯7月6日丨港A兩市醫藥股全線暴跌,A股復星醫藥跌停,泰格醫藥、美迪西、愛爾眼科、康龍化成等跌幅均超10%,港股藥明生物、復星醫藥、泰格醫藥、錦欣生殖、昭衍新藥等均跌超10%。有分析人士指出,醫藥股暴跌主要有兩個原因:一是CDE發佈關於公開徵求《以臨牀價值為導向的抗腫瘤藥物臨牀研發指導原則》,市場解讀成利空,導致CRO概念股全線大跌;二是醫藥板塊前期漲幅較大,獲利盤較多,近期市場整體調整,在CRO概念的大跌拖累下,導致整個板塊今日出現明顯波動。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.